Search Within

Hematology-Oncology Fellows

  1. "2024"
Formats
  1. Meeting Abstract (126)
  2. Journal Article (119)
  3. Review (28)
  4. Editorial (11)
  5. Research Letter (8)
  6. Correspondence (4)
  7. Book Section (2)
  8. Guidelines (1)
Groups
  1. Graduate Medical Education (261)
  2. GME, Medicine (258)
  3. Department of Medicine (230)
  4. Weinberg Fellows (161)
  5. Solid Tumor Oncology Division (139)
  6. Hematologic Malignancies, Division of (137)

More Groups

People
  1. Michael Scordo (28)
  2. Gunjan Shah (27)
  3. Saad Usmani (24)
  4. Sergio Giralt (24)
  5. Kylee Maclachlan (22)
  6. Ross Firestone (22)

More People

Years
  1. 2024 (299)
Publications
  1. Journal of Clinical Oncology (67)
  2. Blood (30)
  3. Clinical Lymphoma, Myeloma and Leukemia (11)
  4. Annals of Oncology (10)
  5. Blood Advances (9)
  6. Clinical Cancer Research (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (74)
  2. American Society of Hematology (42)
  3. Elsevier Inc. (36)
  4. Nature Publishing Group (28)
  5. American Association for Cancer Research (17)
  6. Oxford University Press (16)

More Publishers

Results (299)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic determinants of resistance to anti-BCMA chimeric antigen receptor T-cell (CART) therapies in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Maura, F.; Freeman, C. L.; Lee, H.; Maclachlan, K. H.; Durante, M.; Ziccheddu, B.; Menges, M.; Diamond, B.; Papadimitriou, M.; Silva, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: A multicenter analysis
    Meeting Abstract

    Epstein-Peterson, Z. D.; Lionel, A. C.; Joseph, A.; Drill, E.; Atallah-Yunes, S. A.; Brooks, T. R.; Chong, E. A.; Chong, E. R.; Dela Cruz, J.; Frank, M. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • New treatment approaches in muscle-invasive bladder cancer
    Book Section

    Gupta, A.; Rosenberg, J. E.
    In Knowles, M. A.; Dyrskjøt, L. (Eds.) Biology of Bladder Cancer: From Molecular Insights to Clinical Strategies (2024)

    Fulltext@MSK | Save
  • Efficacy and safety profile of mirvetuximab in folate receptor alpha-positive ovarian cancer
    Meeting Abstract

    Johannet, P.; Foote, M.; Cohen, S.; Friedman, C.; Green, A.; Guo, R.; Hensley, M.; Konner, J.; Kyi, C.; Liu, Y.; more...
    International Journal of Gynecological Cancer (2024)

    Fulltext@MSK | Save
  • Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas
    Meeting Abstract

    Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma
    Meeting Abstract

    Babatunde, O.; Rosenbaum, E.; Kelly, C. M.; Desir-Camille, R.; Keohan, M. L.; Banks, L.; Avutu, V.; Chan, J.; Reed, D.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with the PD-1 inhibitor retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M.; Movva, S.; Kelly, C. M.; Chan, J.; Chi, P.; Banks, L.; Keohan, M. L.; Gounder, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • First-line immunotherapy versus BRAF and MEK inhibitors for patients with BRAF V600E mutant metastatic non-small cell lung cancer
    Meeting Abstract

    Di Federico, A.; Chen, M. F.; Pagliaro, A.; Ogliari, F. R.; Stockhammer, P.; Aldea, M.; Grant, M.; De Giglio, A.; Alessi, J. V.; Pecci, F.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
    Meeting Abstract

    Betof Warner, A.; Smithy, J. W.; Los, C.; Kalvin, H.; Hasson, N.; Amaria, R. N.; Andrade Czapla, J. A.; Schollenberger, M.; furness, A.; Hassel, J. C.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save